ADXN Addex Therapeutics: שווי הפעילות העסקית

The financial price chart for Addex Therapeutics (ADXN) demonstrates an enterprise value of 2.22. Addex Therapeutics develops neuropreparations through partnerships with global corporations and the acquisition of patents. Trial stability is ensured by streamlined raw material supply chains from various foreign suppliers. The business relies on the creation of specific receptor modulators, whose exclusive legal protection guarantees the profitability of future medical developments.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization with net debt to eliminate liquidity distortions. Analyzing the operational value (EV) of Addex Therapeutics allows for the tracking of its actual financial leverage, which is critical while the development of allosteric modulators with global partners is still maturing and not yet generating an immediate cash effect.